scholarly journals Serotonin Transporter Availability in Early Stage Parkinson’s Disease and Multiple System Atrophy

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
S. R. Suwijn ◽  
H. W. Berendse ◽  
C. V. M. Verschuur ◽  
R. M. A. de Bie ◽  
J. Booij
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multiple System Atrophy ◽  
Dopamine Transporter ◽  
Serotonin Transporter ◽  
Disease Duration ◽  
Early Stage ◽  
Spect Imaging ◽  
Parkinsonian Syndrome ◽  
Atypical Parkinsonian Syndrome

Background. Differentiating Parkinson’s disease (PD) from multiple system atrophy (MSA) can be challenging especially early in the course of the disease. Previous studies have shown that midbrain serotonin transporter (SERT) availability in patients with established MSA was significantly lower compared to PD. It is unknown if this is also true for early-stage patients. Methods. 77 early-stage, untreated PD patients were recruited between 1995 and 1998, underwent [123I]β-CIT SPECT imaging, and were followed for at least five years. 16 patients were lost to followup, and in 4 the diagnosis was changed to another atypical parkinsonian syndrome, but not in MSA. In 50 patients, the PD diagnosis was unchanged at followup. In seven patients, the diagnosis was changed to MSA at followup. We retrospectively assessed baseline midbrain SERT availability as well as midbrain SERT-to-striatal dopamine transporter (DAT) ratios. Results. No difference in baseline [123I]β-CIT SERT availability was found. The midbrain SERT-to-striatal DAT ratio for whole striatum was significantly lower in patients with PD compared to MSA (P=0.049). However, when adjusting for the disease duration at imaging this difference is not significant (P=0.070). Conclusion. Midbrain SERT availability is not different between early-stage PD and MSA. Therefore, SERT imaging is not useful to differentiate between early PD and MSA.

scholarly journals Experimental pain sensitivity in multiple system atrophy and Parkinson's disease at an early stage

2016 ◽  
Vol 20 (8) ◽  
pp. 1223-1228 ◽  
Author(s):  
V. Mylius ◽  
S. Pee ◽  
H. Pape ◽  
M. Teepker ◽  
M. Stamelou ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multiple System Atrophy ◽  
Pain Sensitivity ◽  
Early Stage ◽  
Experimental Pain ◽  
Experimental Pain Sensitivity

scholarly journals Differentiation of Parkinson’s disease and Parkinsonism predominant multiple system atrophy in early disease stages by means of objective measurement in Susceptibility Weighted Imaging

2021 ◽  
Author(s):  
Qingguo Ren ◽  
Yihua Wang ◽  
Xiaomin Nan ◽  
Jianyuan Zhang ◽  
Xiangshui Meng ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multiple System Atrophy ◽  
Signal Intensity ◽  
Early Stage ◽  
Region Of Interest ◽  
Final Diagnosis ◽  
Susceptibility Weighted Imaging ◽  
Lentiform Nucleus ◽  
Potential Marker

Abstract Background We have established radiological protocol and made morphological measurement of the lentiform nucleus (LN) and the signal intensity which we used to discriminate parkinsonism predominant multiple system atrophy (MSA-P) from Parkinson’s disease (PD). But we don’t know whether it works especially in early stage of MSA-P. This case-control study aimed to investigate whether the new measurement of the morphological and intensity changes in susceptibility weighted imaging (SWI) of the LN could discriminate MSA-P from PD in their early stage and controls. Methods We retrospectively enrolled patients with MSA-P, PD, and sex- and age-matched controls between January 2015 and July 2020 at the Movement Disorder Center who underwent brain MR scanning with SWI sequence. Two specialists at the center reviewed the medical records and made the final diagnosis, and two experienced neuroradiologists performed MRI image analysis based on a defined radiological protocol to conduct the region of interest (ROI) based morphological measurements of the LN and the signal intensity. Results A total of 17 patients with MSA-P, 17 patients with PD within 2 years of the disease duration and 17 controls were enrolled in this study. We found that patients with MSA-P had significant decreased size in the short line (SL, cSL), and the ratio of the SL and the long line (SLLr, cSLLr) compared with the patients with PD and with the controls (P < 0.05). Combining these four indexes, this finding had a sensitivity of 58.8% and a specificity of 100% to distinguish MSA-P from PD. Conclusions As compared to PD and control subjects, the MSA-P patients are characterized by narrowing morphology of the posterior region of LN. The quantitative morphological change is a possible potential marker to differentiate MSA-P from PD in the early stage.

Sign in / Sign up

Export Citation Format

Share Document